Myeloma Genetics what do we know and where are we going?
|
|
- Anissa Grant
- 6 years ago
- Views:
Transcription
1 in partnership with Myeloma Genetics what do we know and where are we going? Dr Brian Walker Thames Valley Cancer Network 14 th September 2015 Making the discoveries that defeat cancer
2 Myeloma Genome: Summary 2 Primary events: IGH translocations t(4;14) t(6;14) t(11;14) t(14;16) t(14;20) Hyperdiploidy Secondary events: t(8;14) Copy Number Abnormalities: Deletions: 1p, 6q, 8p, 12p, 13q, 14q, 16q, 17p Gains: 1q+, trisomic chromosomes Morgan, Walker & Davies Nat Rev Cancer :335
3 Myeloma Disease Progression 3 Morgan, Walker & Davies Nat Rev Cancer :335
4 The Incidence of Abnormality Changes With Disease Progression 4 Abnormality MGUS (%) SMM (%) MM (%) t(4;14) t(11;14) t(14;16) t(14;20) 5 <1 1.5 del(13q) del(17p) q del(cdkn2c) Ross et al. Haematologica :1221 Leone et al. Clinical Cancer Research :6033 Lopez-Corral et al. Clinical Cancer Research :1692
5 Mutation Number Increases as Disease Progresses Walker et al. Leukemia 2013
6 Genetic Prognostic Markers in Myeloma Translocations t(4;14) t(14;16) t(14;20) vs months 32.9 vs months 16.9 vs months t(11;14) t(6;14) Adverse vs Neutral 51.6 vs months Not reached vs months 25.8 vs months
7 Genetic Prognostic Markers in Myeloma Copy Number Changes 7 del(1p32.3) Gain 1q 34.5 months >70 months 52.1 months >70 months del(13q) del(17p) >70 months >70 months 37 months 40.9 months 67.8 months Walker et al Blood 116:e56
8 Inter-relationship of Adverse Lesions 8 Genetic abnormalities are not solitary events and can occur together Strong positive association with adverse IGH and 1q+ -72% of IGH translocations with 1q+ 16/418 (4%) samples had all three poor markers Boyd et al. Leukemia 2011
9 Impact of Combined Lesions 9 The number of adverse markers has an additive effect on overall survival 60 months 40 months 23.4 months 9.1 months A significant proportion of patients with no adverse lesions still die early Boyd et al. Leukemia 2011
10 Genome Sequencing in Myeloma 10 There is no unifying mutation in myeloma Most frequently mutated genes found at 20% in untreated patients Requires biological pathway analysis Identified NF-κB pathway, histone modifying enzymes and RNA processing as enriched pathways
11 The Prevalence of Somatic Mutations 11 Alexandrov et al. Nature 2013
12 UK Myeloma XI Trial Genomic Strategy newly diagnosed myeloma patients Copy Number Analysis MLPA Translocation Determination qpcr Targeted Sequencing Mutational Analysis Exome Sequencing Biochemical Data β 2 m, Serum Albumin Clinical Data Patient characteristics, PFS, OS
13 UK Myeloma XI Trial Overview 13 Intensive (n=261) Non-intensive (n=202) Randomise Randomise CTD (n=132) CRD (n=129) CTDa (n=99) CRDa (n=103) Assess response Assess response NC + PD CR + VGPR PR + MR NC + PD CR + VGPR PR + MR Randomise (n=60) Randomise (n=25) CVD (n=14) Nothing (n=27) CVD (n=33) CVD (n=10) Nothing (n=12) CVD (n=13) Assess response Assess response Assess response Assess response High-dose melphalan + ASCT Assess response Randomise No maintenance (n=105) Lenalidomide (n=106) Lenalidomide + Vorinostat (n=42)
14 The Mutational Landscape of Myeloma 14
15 RAS Pathways 15
16 RAS Pathway Mutations Summary 16 KRAS 21%, NRAS 19%, BRAF 7% at presentation Myeloma is a disease characterised deregulation of the RAS/MAPK pathway so may constitute good clinical targets No prognostic value with current treatments Walker et al. JCO 2015
17 Results: interaction between genetic abnormalities Positive correlations: t(11;14) and CCND1 t(4;14) and FGFR3 t(4;14) and PRKD2 del(17p) and TP53 del(13q) and DIS3 Negative correlations NRAS and KRAS Hyperdiploïdy and translocations Co-segregation of the adverse prognostic features Walker et al. JCO 2015
18 Results: IRF4 and positive outcome Transcription factor Mutated in 3.2% of patients Most common is K123R Not the same as CLL (L116R) Walker et al. JCO 2015
19 Results: IRF4 and positive outcome Shaffer AL, Nature, 2008
20 Results: EGR1 and positive outcome Mutated in 3.5% of patients Transcriptional regulator The biological role of mutations at the 5 end of EGR1 remains to be ascertained (?activating) EGR1 has been involved in Myeloma at the expression level: in the recruitment of MYC to promote the p53-independent apoptosis and in response Bortezomib treatment In the response to IMiDs as it is one of the candidate genes for del(5q) myelodysplastic syndromes Walker et al. JCO 2015
21 Results: Adverse prognostic features 21 We identified in our cohort a series of genes associated with an adverse prognosis. - Some of them were expected and/or had previously been described - TP53 mutations (3%) - ATM (3%) and ATR (2%) mutations - Some were novel - CCND1 mutations (2.2%) - ZFHX4 mutations (4.0%) - NCKAP5 mutations (2.2%) Gene PFS present PFS absence p-value 2y OS Present 2y OS Absent p-value Frequency ZFHX < % 80% NS 4% TP % 81% % ATM/ATR mutations % 81% % CCND NS 38% 80% % NCKAP NS 53% 80% % Walker et al. JCO 2015
22 Poor Prognostic Genetic Markers 22 CKS1B PFS CKS1B OS TP53 PFS TP53 OS ATM/ATR PFS ATM/ATR OS Walker et al. JCO 2015
23 Poor Prognostic Genetic Markers 23 ZFHX4 PFS CCND1 OS NCKAP5 OS Walker et al. JCO 2015
24 Results: Multivariate Analysis 24 C=0.69, optimism 0.01 Walker et al. JCO 2015
25 Results: Cumulative impact on survival (ISS-FISH) 25 The more adverse features are present, the worse the outcome is Nevertheless, 35% of patients that progress before 18 months do not have an adverse lesion 25% of patients that die before 24 months do not have an adverse feature Walker et al. JCO 2015
26 26 Results: Improved prognostic discrimination using ISS-MUT Group I: Group II: Or ISSI/II no CNSA/mut ISS III no CNSA/mut ISS I/II/III +1 CNSA/mut Group III: 2+ CNSA/mut Walker et al. JCO 2015
27 Results: Improved prognostic discrimination using ISS-MUT Walker et al. JCO 2015
28 The relevance of intra-clonal heterogeneity to myeloma 28 Multiple Myeloma Many sites at which tumour cells reside in the body Each population is derived from a common ancestor But, each population may evolve independently mutations may be present at one site but not another Over time clonal dominance will change clonal tiding differential responses to treatment over time
29 Darwinian evolution through natural selection 29 Genetic analyses (FISH, NGS ) have unravelled intratumour heterogeneity. Branching or Darwinian evolution in many different human cancers (ALL, breast cancer, gastric cancers ) Anderson et al Nature 2011, Nik-Zainal et al Cell 2012, Gerlinger et al NEJM 2012 Understanding intraclonal heterogeneity and tumour evolution will be key to improve targeted therapies, and to describe the mechanisms of treatment-resistance Greaves M & Maley C, Nature, 2012
30 A Model of Myeloma Disease Progression COMPETITION AND SELECTIVE PRESSURE MIGRATION AND FOUNDER EFFECT Clonal advantage Myeloma progenitor cell TUMOUR CELL DIVERSITY GENETIC LESIONS Morgan G, et al. Nat Rev Cancer. 2012;12:
31 Clonal Dynamics in High Risk Myeloma 31 8 FISH assays to interrogate clonal dynamics of one patient Keats et al., Blood (2012)
32 Patients and Methods 32 Whole Exome Sequencing Alignment, calibration, and de-duplication 463 samples from NCRI Myeloma XI trial (NCT ) CD138+ cells as tumour DNA WCP as normal DNA HiSeq 2000 Illumina FastQC BWA Stampy GATK Picard Mutation Calling MuTect Variants filtering SnpEff Oncotator Copy number assessment Control-FREEC MLPA data Measurement of Sub-clonal diversity GAUCHO Number of mutations Mutated genes Mutation signatures Somatic aberrations Hyperdiploidy Cancer clonal fraction Number of sub-clones Berger-Parker index Inverse Simpson index
33 Determining heterogeneity at the single cell level 33 BM aspiration CD138+ cell purification DNA isolation Fixed/Frozen Cells MM Patient Whole Exome Sequencing Single Cell Analysis List of Mutations List of Genomic Aberrations Clonal phylogeny
34 A linear pattern of MM evolution 34 - Consecutive accumulation of somatic mutations and genomic aberrations Melchor L et al Leukemia 2014
35 A linear pattern of MM evolution 35 - Consecutive accumulation of somatic mutations and genomic aberrations Melchor L et al Leukemia 2014
36 A branching pattern of MM evolution 36 Divergent clonal lineages arise from common clonal ancestors Melchor L et al Leukemia 2014
37 A branching pattern of MM evolution 37 Divergent clonal lineages arise from common clonal ancestors Melchor L et al Leukemia 2014
38 Parallel evolution in MM 38 Under the same selective pressure and environmental conditions, independent but not far-related clones may acquire similar mutations conferring growth and selective advantages For example, a patient with both an NRAS and KRAS mutation Melchor L et al Leukemia 2014
39 Parallel evolution in MM 39 Melchor L et al Leukemia 2014
40 RAS mutations subclonal heterogeneity 40
41 Cancer Evolutionary Trees 41 Hairy Cell Leukaemia Myeloma Solid Cancer Common BRAF V600 mutation 5 NS SNVs No common mutations Primary translocations/hyperdiploidy 25 NS SNVs No common mutations No common translocations 540 NS SNVs
42 Chop down the trunk, don t aim for the branches? 42 BRAF inhibitors RAS inhibitors BRD inhibitors Copy Number Abnormalities Primary Translocations/ Hyperdiploidy DNA methylation inhibitors MMSET/CCNDx inhibitors
43 43
Smouldering Myeloma: to treat or not to treat?
Smouldering Myeloma: to treat or not to treat? Massimo Offidani Clinica di Ematologia Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona Definitions and epidemiology 3000-5000 new SMM/year in
More informationMYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival
in partnership with MYC Translocations In Multiple Myeloma Involve Recruitment Of Enhancer Elements Resulting In Over- Expression and Decreased Overall Survival Brian A Walker Centre for Myeloma Research,
More informationMyeloma cytogenetics: a personal and historical perspective. Fiona Ross UKMF 19/03/2014
Myeloma cytogenetics: a personal and historical perspective Fiona Ross UKMF 19/03/2014 Chromosome abnormalities in myeloma Abnormal myeloma karyotypes started to be published in 1970s but many cases throughout
More informationBiology of high risk multiple myeloma. Nicola Giuliani, PhD MD Associate Professor of Hematology University of Parma
Biology of high risk multiple myeloma Nicola Giuliani, PhD MD Associate Professor of Hematology University of Parma Hallmarks of high-risk multiple myeloma (MM) 20-30% 1,2 Clinical aggressive behaviour
More informationPersonalizing Myeloma Treatment Drugs and Strategies
Personalizing Myeloma Treatment Drugs and Strategies PD Dr. med. Marc S. Raab Heidelberg University Medical Center & German Cancer Research Center Multiple Myeloma Clonal proliferation of malignant plasma
More informationResearch Strategy: 1. Background and Significance
Research Strategy: 1. Background and Significance 1.1. Heterogeneity is a common feature of cancer. A better understanding of this heterogeneity may present therapeutic opportunities: Intratumor heterogeneity
More informationREVIEWS 1. Genomic complexity of multiple myeloma and its clinical implications
Genomic complexity of multiple myeloma and its clinical implications Salomon Manier 1,, Karma Z. Salem 1,, Jihye Park 1,, Dan A. Landau 3,, Gad Getz,5 and Irene M. Ghobrial 1, Abstract Multiple myeloma
More informationThe role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia
The role of cytogenomics in the diagnostic work-up of Chronic Lymphocytic Leukaemia Adrian Zordan, Meaghan Wall, Ruth MacKinnon, Pina D Achille & Lynda Campbell Victorian Cancer Cytogenetics Service (VCCS)
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationClonal heterogeneity and MRD testing in multiple myeloma
Clonal heterogeneity and MRD testing in multiple myeloma June 24, 2016 Sham Mailankody, MBBS Assistant Attending Physician Myeloma Service, Memorial Sloan-Kettering Cancer Center New York www.mskcc.org
More informationPlease Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
More informationNature Genetics: doi: /ng Supplementary Figure 1. Rates of different mutation types in CRC.
Supplementary Figure 1 Rates of different mutation types in CRC. (a) Stratification by mutation type indicates that C>T mutations occur at a significantly greater rate than other types. (b) As for the
More informationThis is a repository copy of Neutral tumor evolution in myeloma is associated with poor prognosis.
This is a repository copy of Neutral tumor evolution in myeloma is associated with poor prognosis. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/121045/ Version: Accepted
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationARTICLE RESEARCH. Macmillan Publishers Limited. All rights reserved
Extended Data Figure 6 Annotation of drivers based on clinical characteristics and co-occurrence patterns. a, Putative drivers affecting greater than 10 patients were assessed for enrichment in IGHV mutated
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationSignaling Pathway Profiling in Multiple Myeloma. Marc S. Raab, MD PhD
Signaling Pathway Profiling in Multiple Myeloma Marc S. Raab, MD PhD Intro 1. Chromosomal abnormalities: Primary Secondary Myeloma genomics Hyperdiploidy: Trisomies of odd numbered chromosome (3, 5, 7,
More informationThis is a repository copy of APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
This is a repository copy of APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/87492/
More informationGenetic prognostication and treatment selection in Multiple Myeloma. Kihyun Kim Department of Medicine Sungkyunkwan University Samsung Medical Center
Genetic prognostication and treatment selection in Multiple Myeloma Kihyun Kim Department of Medicine Sungkyunkwan University Samsung Medical Center The International Congress of BMT 2018 COI disclosure
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationHaematology Probes for Multiple Myeloma
Haematology Probes for Multiple Myeloma MULTIPLE MYELOMA Multiple myeloma (MM) is a plasma cell neoplasm, characterised by the accumulation of clonal plasma cells in the bone marrow and by very complex
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationMolecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note
Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note MPEP/MPC Advice Note 2016-02 June 2016 Test evaluated: Tumour Protein p53 (TP53) Molecular Pathology Evaluation Panel
More informationSupplemental Figure legends
Supplemental Figure legends Supplemental Figure S1 Frequently mutated genes. Frequently mutated genes (mutated in at least four patients) with information about mutation frequency, RNA-expression and copy-number.
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationMolecular Markers. Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC
Molecular Markers Marcie Riches, MD, MS Associate Professor University of North Carolina Scientific Director, Infection and Immune Reconstitution WC Overview Testing methods Rationale for molecular testing
More informationGenomic complexity and arrays in CLL. Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy
Genomic complexity and arrays in CLL Gian Matteo Rigolin, MD, PhD St. Anna University Hospital Ferrara, Italy Clinical relevance of genomic complexity (GC) in CLL GC has been identified as a critical negative
More information1 Diagnosis and Genetic Classification of Multiple Myeloma
1 Diagnosis and Genetic Classification of Multiple Myeloma INTRODUCTION In the past decade we have seen great advances in our understanding of the genetic abnormalities present in multiple myeloma (MM)
More informationEpigenetic programming in chronic lymphocytic leukemia
Epigenetic programming in chronic lymphocytic leukemia Christopher Oakes 10 th Canadian CLL Research Meeting September 18-19 th, 2014 Epigenetics and DNA methylation programming in normal and tumor cells:
More informationFigure S4. 15 Mets Whole Exome. 5 Primary Tumors Cancer Panel and WES. Next Generation Sequencing
Figure S4 Next Generation Sequencing 15 Mets Whole Exome 5 Primary Tumors Cancer Panel and WES Get coverage of all variant loci for all three Mets Variant Filtering Sequence Alignments Index and align
More informationUpdate on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
More informationWhole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute
Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationBCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos
BCR ABL1 like ALL: molekuliniai mechanizmai ir klinikinė reikšmė. IKAROS delecija: molekulinė biologija, prognostinė reikšmė. ASH 2015 naujienos Ph like ALL BCR ABL1 like acute lymphoblastic leukemia (ALL)
More informationMutational Impact on Diagnostic and Prognostic Evaluation of MDS
Mutational Impact on Diagnostic and Prognostic Evaluation of MDS Elsa Bernard, PhD Papaemmanuil Lab, Computational Oncology, MSKCC MDS Foundation ASH 2018 Symposium Disclosure Research funds provided by
More informationRetrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma
930 Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma NIAN LIU, HEBING ZHOU, GUANGZHONG YANG, CHUANYING GENG, YUAN JIAN, HUAN GUO and WENMING CHEN Department
More informationAcute leukemia and myelodysplastic syndromes
11/01/2012 Post-ASH meeting 1 Acute leukemia and myelodysplastic syndromes Peter Vandenberghe Centrum Menselijke Erfelijkheid & Afdeling Hematologie, UZ Leuven 11/01/2012 Post-ASH meeting 2 1. Acute myeloid
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationSeptember 20, Submitted electronically to: Cc: To Whom It May Concern:
History Study (NOT-HL-12-147), p. 1 September 20, 2012 Re: Request for Information (RFI): Building a National Resource to Study Myelodysplastic Syndromes (MDS) The MDS Cohort Natural History Study (NOT-HL-12-147).
More informationPersonalised medicine: Past, present and future
Kathmandu, Bir Hospital visit, August 2018 Personalised medicine: Past, present and future Rodney J. Scott University of Newcastle, NSW, Australia & Hunter Area Pathology Service Current Medical Care Started
More informationmsmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma
msmart Mayo Stratification for Myeloma And Risk-adapted Therapy Newly Diagnosed Myeloma msmart Multiple myeloma is increasingly recognized as more than one disease, characterized by marked cytogenetic,
More information5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff
5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late
More informationDefined lymphoma entities in the current WHO classification
Defined lymphoma entities in the current WHO classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno Bellinzona, January 29-31, 2016 Evolution of lymphoma classification Rappaport Lukes
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationGenomic Landscape and Mechanisms of Disease Evolution and Progression in Multiple Myeloma
Genomic Landscape and Mechanisms of Disease Evolution and Progression in Multiple Myeloma Malin Hultcrantz, MD, PhD, and Ola Landgren, MD, PhD Abstract Multiple myeloma (MM) is a plasma cell malignancy,
More informationImportance of minor TP53 mutated clones in the clinic
Importance of minor TP53 mutated clones in the clinic Davide Rossi, M.D., Ph.D. Hematology IOSI - Oncology Institute of Southern Switzerland IOR - Institute of Oncology Reserach Bellinzona - Switzerland
More informationDouble hit lymphoma Clinical perspectives
Double hit lymphoma Clinical perspectives Peter Johnson Some definitions, for clarity Double-hit lymphoma (5% of DLBL) Rearranged MYC (8q24) by FISH Plus either rearranged BCL2 (18q21) or BCL6 (3q27) Double-expression
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationManagement of high-risk disease
Management of high-risk disease Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria: BMS,
More information1. What to test. 2. When to test
Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Biomarkers: the triad of questions 1. What to test 2. When to test 3. Who to test Impact of CLL biological features on
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationClonal Evolution of saml. Johnnie J. Orozco Hematology Fellows Conference May 11, 2012
Clonal Evolution of saml Johnnie J. Orozco Hematology Fellows Conference May 11, 2012 CML: *bcr-abl and imatinib Melanoma: *braf and vemurafenib CRC: *k-ras and cetuximab Esophageal/Gastric: *Her-2/neu
More informationObjectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013
Molecular Markers in Hematologic Malignancy: Ways to locate the needle in the haystack. Objectives Review the types of testing for hematologic malignancies Understand rationale for molecular testing Marcie
More informationSummary... 2 TRANSLATIONAL RESEARCH Tumour gene expression used to direct clinical decision-making for patients with advanced cancers...
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 TRANSLATIONAL RESEARCH... 3 Tumour gene expression used to direct clinical decision-making for patients with advanced
More informationClinical Interpretation of Cancer Genomes
IGENZ Ltd, Auckland, New Zealand Clinical Interpretation of Cancer Genomes Dr Amanda Dixon-McIver www.igenz.co.nz 1992 Slovenia and Croatia gain independence USA and Russia declare the Cold War over Steffi
More informationStudy Objectives: GMMG MM5
Study Objectives: GMMG MM5 1.) Demonstration of non-inferiority of VCD induction therapy compared to PAd induction therapy with respect to response rate (very good partial remission or better; response
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationI nuovi fa*ori di classificazione e di rischio del Mieloma smouldering.
Dipartimento di Scienze Biomediche e Oncologia Umana Unità per lo Studio e la Terapia delle Gammopatie Monoclonali I nuovi fa*ori di classificazione e di rischio del Mieloma smouldering. Roberto Ria, M.D.
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationTreatment Landscape in R/R DLBCL Novel Targets and Strategies. Wyndham H. Wilson, M.D., Ph.D. Senior Investigator
Treatment Landscape in R/R DLBCL Novel Targets and Strategies Wyndham H. Wilson, M.D., Ph.D. Senior Investigator Gene-expression profiling of DLBCL subtypes Roschewski, M. et al. (2013) Nat. Rev. Clin.
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationCorrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run
Corrigenda WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run In addition to corrections of minor typographical errors, corrections
More informationPathology of the indolent B-cell lymphomas Elias Campo
Pathology of the indolent B-cell lymphomas Elias Campo Hospital Clinic, University of Barcelona Small B-cell lymphomas Antigen selection NAIVE -B LYMPHOCYTE MEMORY B-CELL MCL FL LPL MZL CLL Small cell
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationQué hemos aprendido hasta hoy? What have we learned so far?
Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;
More informationDisclosures. Outlines. Plasma Cell Neoplasms 10/31/2017. I have nothing to disclose. Pei Lin, M. D. Updated diagnostic criteria (DD)
Plasma cell Neoplasms Disclosures I have nothing to disclose. Pei Lin, M. D. Outlines Updated diagnostic criteria (DD) Myeloma phenotype and MRD detection by MFC Identifying high risk patients MRD, FISH,
More informationReporting TP53 gene analysis results in CLL
Reporting TP53 gene analysis results in CLL Mutations in TP53 - From discovery to clinical practice in CLL Discovery Validation Clinical practice Variant diversity *Leroy at al, Cancer Research Review
More informationSureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationXIII. Molecular pathogenesis of transformed lymphomas
Hematological Oncology Hematol Oncol 2015; 33: 70 74 Published online in Wiley Online Library (wileyonlinelibrary.com).2221 Supplement Article XIII. Molecular pathogenesis of transformed lymphomas Davide
More informationCancer Genomics. Nic Waddell. Winter School in Mathematical and Computational Biology. July th
Cancer Genomics Nic Waddell Winter School in Mathematical and Computational Biology 6th July 2015 Time Line of Key Events in Cancer Genomics Michael R. Stratton Science 2011;331:1553-1558 The Cancer Genome
More informationP53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse
Blood First Edition Paper, prepublished online August 31, 2004; DOI 10.1182/blood-2004-04-1363 P53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse Prognostic Factor for Patients
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationSupplementary Figure 1. Estimation of tumour content
Supplementary Figure 1. Estimation of tumour content a, Approach used to estimate the tumour content in S13T1/T2, S6T1/T2, S3T1/T2 and S12T1/T2. Tissue and tumour areas were evaluated by two independent
More informationOverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA
OverView Circulating Nucleic Acids (CFNA) in Cancer Patients Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA cfna Blood Assays Cell-free nucleic acids as biomarkers in cancer patients.
More informationOutline. Chromosomal analysis FISH. Chromosomal abnormalities in cancer. Clinical application of cytogenetics. Procedure Nomenclature
Outline Chromosomal analysis Procedure Nomenclature FISH Procedure Probes Multicolor-FISH CGH Chromosomal abnormalities in cancer CML, MPD, MDS, AML, ALL, CLL, myeloma, lymphoma Clinical application of
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationTEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationOncology Cytogenetics Diagnostic Service - User Guide 2014
Oncology Cytogenetics Diagnostic Service - User Guide 2014 Contact details Address: Cytogenetics Department 5 th Floor Tower Wing Guy s Hospital Great Maze Pond London SE1 9RT General enquiries 0207 188
More informationNeutral evolution in colorectal cancer, how can we distinguish functional from non-functional variation?
in partnership with Neutral evolution in colorectal cancer, how can we distinguish functional from non-functional variation? Andrea Sottoriva Group Leader, Evolutionary Genomics and Modelling Group Centre
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationAD (Leave blank) TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients
AD (Leave blank) Award Number: W81XWH-12-1-0444 TITLE: Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients PRINCIPAL INVESTIGATOR: Mark A. Watson, MD PhD CONTRACTING ORGANIZATION:
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationComprehensive Analyses of Circulating Cell- Free Tumor DNA
Comprehensive Analyses of Circulating Cell- Free Tumor DNA Boston, MA June 28th, 2016 Derek Murphy, Ph.D. Scientist, Research and Development Personal Genome Diagnostics Acquisition of Somatic Alterations
More informationLiposarcoma*Genome*Project*
LiposarcomaGenomeProject July2015! Submittedby: JohnMullen,MD EdwinChoy,MD,PhD GregoryCote,MD,PhD G.PeturNielsen,MD BradBernstein,MD,PhD Liposarcoma Background Liposarcoma is the most common soft tissue
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationNovel treatment options for Waldenstrom Macroglobulinemia
Novel treatment options for Waldenstrom Macroglobulinemia Irene Ghobrial, MD Associate Professor of Medicine Harvard Medical School Dana Farber Cancer Institute Boston, MA Ghobrial et al, Lancet Oncol
More informationReview of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM
Review of the recent publications from the French group of myeloma on urine vs serum FLC analysis in MM Multiple myeloma Response evaluation Kumar Lancet Oncol 2016; 17: e328 46 Cumulative Proportion Surviving
More informationIs Myeloma Curable in 2012?
Is Myeloma Curable in 2012? YES Cure is living long enough to die of another cause April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist,
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More information